SD HEALTHCARE
Recent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...
FDA Approves Remdesivir to Treat COVID-19
The U.S. Food and Drug Administration approved its first COVID-19 treatment: Gilead Science Inc.’s antiviral drug remdesivir. The FDA and Foster City-based Gilead (Nasdaq: GILD) announced the news on Oct. 22.
Biocom and centrexIT Partner to Launch IT Deal Desk
TECH: Connects Life Science Companies with Over 300 vetted IT Providers
Together, Biocom and centrexIT created IT Deal Desk, a digital platform that provides life science companies with cost-effective IT solutions.
Escient Raises $77.5M Series B
BIOTECH: Co. Testing Its First Drug
San Diego-based biotech Escient Pharmaceuticals, has announced it has raised a $77.5 million Series B funding round and started their first clinical trial.
Biotech Raises Profile Among San Diego’s Public Companies
FINANCE: In Some Cases, Market Caps Almost Quadruple
Every year, the San Diego Business Journal compiles a list of public companies with headquarters in San Diego County. This year’s list seems to tell a story. Call it Rise of the Biotechs.
Micronoma Appoints Magda Marquet to Chairman of the Board
Micronoma has appointed Magda Marquet as chairman of the firm's board.
Illumina Acquires Grail
$8 Billion Deal to Close in 2021
Illumina Inc. (Nasdaq: ILMN), a leading maker of the machines that sequence genes, will pay $8 billion in cash and stock for San Francisco-based Grail, a developer of a blood test that promises to detect cancer early.
Debut Bio Receives $1M Air Force Award
‘Grand Challenge’ Centered On Manufacturing Process
As he was building his biotechnology company, Debut Biotechnology CEO Joshua Britton drove for Uber to get money for legal fees and chemistry supplies. The gig had an advantage in that he could pitch the people riding in the passenger seat for funding.
$1.5 Billion Life Science Campus Planned
DEVELOPMENT: Manchester Pacific Gateway Property to Become Research District
A more than eight-acre chunk of the downtown San Diego waterfront property that had been part of the Manchester Pacific Gateway project will instead become a life science campus with an estimated price tag of about $1.5 billion.
Jumpcode Genomics Sees Opportunity with Kits
BIOTECH: Carlsbad-based Company Emerges from Stealth Mode
Jumpcode Genomics has emerged from stealth mode with technology that aims to turn down the background noise in next-generation sequencing libraries.
Libra Therapeutics Raises $29M
Company Aims to Restore Cellular Balance
Libra Therapeutics, a biotechnology company focused on developing novel disease-modifying therapeutics, has officially launched with $29 million in Series A financing to restore the cellular balance lost in neurodegenerative diseases.
Horton Plaza Ideal for Life Science Firms
REDEVEOPMENT: Former Mall Has Desired Infrastructure, Essential Elements
Stockdale Capital Partners is actively wooing life science firms to move to the reimagined Horton Plaza as work is about to begin on redevelopment of the former Nordstrom building.
Maravai LifeSciences to Expand Manufacturing at TriLink
BIOTECH: Sorrento Mesa Firm Cites Growing Demand for its Products
Maravai LifeSciences has announced plans to expand the contract development and manufacturing organization (CDMO) capabilities at one of its companies, TriLink BioTechnologies, for the second time in less than a year.
Cos. Develop COVID-19 Antibody Treatments
BIOTECH: Allele Biotechnology Using Nanoantibodies from Llamas
Dr. Jiwu Wang was thinking ahead when he purchased a plot of land in Fallbrook to raise llamas about 12 years ago.
Agragene Annouces $4M in Additional Funding
AGRICULTURE: New Investment Again Comes from Ospraie Ag Science
The agriculture-tech sector is growing and Agragene Inc. is attracting attention from investors.
Ionis Pharmaceuticals to Acquire Remaining Stake in Akcea
BIOTECH: Boston Co. Was Spun Out of Ionis, Had IPO in 2017
Ionis Pharmaceuticals plans to acquire the remaining stake in Akcea Therapeutics that it does not already own for approximately $500 million cash.
Prev Next